Advertisement

Topics

Inventiva: Odiparcil Awarded Orphan Drug Designation for the Treatment of MPS VI by the FDA

11:47 EDT 10 Aug 2017 | FinanzNachrichten

Odiparcil therapeutic potential and significant benefit over existing therapeutic options confirmed With a high medical need still existing, odiparcil could significantly improve the treatment opt...

Original Article: Inventiva: Odiparcil Awarded Orphan Drug Designation for the Treatment of MPS VI by the FDA

NEXT ARTICLE

More From BioPortfolio on "Inventiva: Odiparcil Awarded Orphan Drug Designation for the Treatment of MPS VI by the FDA"

Quick Search
Advertisement